The US chipmaker Qualcomm has decided to file an appeal to the Supreme Court of South Korea regarding a decision from a lower court which rejected the company’s appeal of an order from the South Korean Fair Trade Commission (KFTC) that resulted in the largest fine in Korean history, the company said Tuesday, September 5.
After nearly three years of investigation, the KFTC found Qualcomm guilty of monopolistic practices in December, ordering the chipset maker to pay about US$850 million in penalties. The commission said Qualcomm had an “unfair business model” that helped it more than double its share of the LTE chip market to 69% from 34% in 2010 over five years.
The KFTC order came after Qualcomm agreed in 2015 to pay a fine amounting to almost US$1 billion in China, where it was investigated for monopolising the market.
Qualcomm said it would appeal the Seoul High Court ruling, which rejected the company’s initial appeal of the KFTC order earlier on Tuesday. The high court ruled the KFTC’s order wouldn’t cause Qualcomm’s business to suffer “irreparable harm.”
“Qualcomm continues to believe that the KFTC’s decision is not supported by the acts and law, and was the product of a hearing and investigation that denied Qualcomm fundamental due process rights,” the company said in its statement.
Full Content: Korea Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Live Nation Under Criminal Antitrust Investigation Over Pandemic-Era Refund Policies
May 19, 2025 by
CPI
BCLP Strengthens Healthcare and Antitrust Litigation Practice
May 19, 2025 by
CPI
Italy Fines AI Chatbot Maker Replika €5 Million Over Privacy Violations
May 19, 2025 by
CPI
Germany’s Antitrust Chief: EU-US Tech Policy Divide Is Mostly Rhetoric
May 19, 2025 by
CPI
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas